Coronavirus disease (COVID-2019) R&D
On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. The coronavirus disease (COVID-2019) was identified as the causative virus by Chinese authorities on 7 January. As part of WHO’s response to the outbreak, the R&D Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus.
COVID-19 Public Health Emergency of International Concern (PHEIC): Global research and innovation forum: towards a research roadmap
On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC).
World scientists on COVID-19 met at the World Health Organization’s Geneva headquarters from 11 to 12 February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and ways to work together to accelerate and fund priority research that can contribute to curtail this outbreak and prepare for future outbreaks.
- DRAFT landscape of COVID-19 candidate vaccines (last updated 21 March 2020)
- WHO R&D Blueprint novel Coronavirus COVID-19 Phase IIb/III Vaccine Trial Synopsis (last updated February 2020)
- Informal consultation on prioritization of candidate vaccines agents for use in novel coronavirus 2019 infection (last updated 30 January 2020)
- Outline of designs for experimental vaccines and therapeutics (last updated 17 January 2020)
- Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection (last updated 13 March 2020)
- Outline of trial designs for experimental therapeutics (last updated 27 January 2020)
- Overview of the types/classes of candidate therapeutics
Read more here.